MICHAEL ITTMANN to Prostatic Neoplasms, Castration-Resistant
This is a "connection" page, showing publications MICHAEL ITTMANN has written about Prostatic Neoplasms, Castration-Resistant.
Connection Strength
1.540
-
Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer. Prostate. 2020 01; 80(1):65-73.
Score: 0.576
-
Cholesterol metabolism regulated by CAMKK2-CREB signaling promotes castration-resistant prostate cancer. Cell Rep. 2025 Jun 24; 44(6):115792.
Score: 0.213
-
Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity. Cancer Res. 2024 03 04; 84(5):703-724.
Score: 0.195
-
MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT. J Clin Invest. 2021 02 15; 131(4).
Score: 0.158
-
Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling. Oncogene. 2021 03; 40(9):1690-1705.
Score: 0.158
-
Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer. Nat Commun. 2016 05 19; 7:11612.
Score: 0.114
-
HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs. 2014 Apr; 32(2):235-242.
Score: 0.092
-
Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. Nat Metab. 2019 01; 1(1):70-85.
Score: 0.034